Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter

Neuropsychopharmacology

Volumn 27, Issue 6, 2002, Pages 914-923

  Holmes, Andrew ^a   Yang, Rebecca J ^a   Murphy, Dennis L ^a   Crawley, Jacqueline N ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Antidepressant; Depression; Desipramine; Fluoxetine; Gene knockout mouse; Serotonin transporter

Indexed keywords

ANTIDEPRESSANT AGENT; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; SEROTONIN TRANSPORTER;

ACETYLATOR PHENOTYPE; ANIMAL EXPERIMENT; ARTICLE; BREEDING; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL TEST; FEMALE; FORCED SWIMMING TEST; GENE MUTATION; IMMOBILIZATION; KNOCKOUT GENE; MALE; MOUSE; MOUSE STRAIN; MUSCLE STRENGTH; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STRAIN DIFFERENCE; WEIGHT GAIN;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; CARRIER PROTEINS; FEMALE; IMMOBILIZATION; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTATION; NERVE TISSUE PROTEINS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 0036897940     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(02)00374-3     Document Type: Article

References (81)

1. Battersby S., Ogilvie A.D., Smith C.A., Blackwood D.H., Muir W.J., Quinn J.P., Fink G., Goodwin G.M., Harmar A.J. Structure of a variable number tandem repeat of the serotonin transporter gene and association with affective disorder. Psychiatr Genet. 6:1996;177-181.
2. Bel N., Artigas F. In vivo effects of the simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function. Microdialysis studies. J Pharmacol Exp Ther. 278:1996;1064-1072.
3. Bengel D., Murphy D.L., Andrews A.M., Wichems C.H., Feltner D., Heils A., Mossner R., Westphal H., Lesch K.P. Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. Mol Pharmacol. 53:1998;649-655.
4. Blakely R.D., Berson H.E., Fremeau R.T. Jr., Caron M.G., Peek M.M., Prince H.K., Bradley C.C. Cloning and expression of a functional serotonin transporter from rat brain. Nature. 354:1991;66-70.
5. Blier P., de Montigny C., Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatments. preclinical evidence J Clin Psychiat. 51S:1990;14-20.
6. Borsini F., Cesana R., Vidi A., Mennini T. Evidence that imipramine activates 5-HT1C receptor function. Eur J Pharmacol. 203:1991;359-363.
7. Borsini F. Role of the serotonergic system in the forced swimming test. Neurosci Biobehav R. 19:1995;377-395.
8. Bourin M., Hascoet M., Colombel M.C., Redrobe J.P., Baker G.B. Differential effects of clonidine, lithium and quinine in the forced swimming test in mice for antidepressants. possible roles of serotoninergic systems Eur Neuropsychopharm. 6:1996;231-236.
9. Brown G.L., Linnoila M.I. CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence. J Clin Psychiat. 51:1990;31-41.
10. Caston J., Devulder B., Jouen F., Lalonde R., Delhaye-Bouchaud N., Mariani J. Role of an enriched environment on the restoration of behavioral deficits in Lurcher mutant mice. Dev Psychobiol. 35:1999;291-303.
11. Cesana R., Ceci A., Ciprandi C., Borsini F. Mesulergine antagonism towards the fluoxetine anti-immobility effect in the forced swimming test in mice. J Pharm Pharmacol. 45:1993;473-475.
12. Chaput Y., de Montigny C., Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology. 5:1991;219-229.
13. Charney D.S. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiat. 59:1998;11-14.
14. Clenet F., De Vos A., Bourin M. Involvement of 5-HT(2C) receptors in the anti-immobility effects of antidepressants in the forced swimming test in mice. Eur Neuropsychopharm. 11:2001;145-152.
15. Collier D.A., Arranz M.J., Sham P., Battersby S., Vallada H., Gill P., Aitchison K.J., Sodhi M., Li T., Roberts G.W., Smith B., Morton J., Murray R.M., Smith D., Kirov G. The serotonin transporter is a potential susceptibility factor for bipolar affective disorder. Neuroreport. 7:1996;1675-1679. a.
16. Collier D.A., Stober G., Li T., Heils A., Catalano M., Di Bella D., Arranz M.J., Murray R.M., Vallada H.P., Bengel D., Muller C.R., Roberts G.W., Smeraldi E., Kirov G., Sham P., Lesch K.P. A novel functional polymorphism within the promoter of the serotonin transporter gene. possible role in susceptibility to affective disorders Mol Psychiatr. 1:1996;453-460. b.
17. Conti A.C., Cryan J.F., Dalvi A., Lucki I., Blendy J.A. cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci. 22:2002;3262-3268.
18. Crawley J.N., Paylor R. A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm Behav. 31:1997;197-211.
19. Crawley J.N. What's Wrong with My Mouse? Behavioral Phenotyping of Transgenic and Knockout mice. 2000;Wiley-Liss, New York.
20. Cryan J.F., Dalvi A., Jin S.H., Hirsch B.R., Lucki I., Thomas S.A. Use of dopamine-beta-hydroxylase-deficient mice to determine the role of norepinephrine in the mechanism of action of antidepressant drugs. J Pharmacol Exp Ther. 298:2001;651-657.
21. Cryan J.F., Lucki I. Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine(2C) receptors. J Pharmacol Exp Ther. 295:2000;1120-1126.
22. David D.J., Nic Dhonnchadha B.A., Jolliet P., Hascoet M., Bourin M. Are there gender differences in the temperature profile of mice after acute antidepressant administration and exposure to two animal models of depression? Behav Brain Res. 119:2001;203-211.
23. Daws L.C., Montanez S., Gould G.G., Owens W.A., Frazer A., Murphy D.L. Influence of genetic knockout (KO) of the serotonin transporter (5-HTT) on kinetics of 5-HT clearance and 5-HT1B receptor regulation of 5-HT clearance in vivo. Soc Neurosci Abstr. 27:2001;814-818.
24. Delgado P.L., Charney D.S., Price L.H., Aghajanian G.K., Landis H., Heninger G.R. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiat. 47:1990;411-418.
25. Delgado P.L., Price L.H., Miller H.L., Salomon R.M., Licinio J., Krystal J.H., Heninger G.R., Charney D.S. Rapid serotonin depletion as a provocative challenge test for patients with major depression. relevance to antidepressant action and the neurobiology of depression Psychopharmacol Bull. 27:1991;321-330.
26. de Montigny C., Chaput Y., Blier P. Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. J Clin Psychiatry. 51S:1991;4-8.
27. Do-Rego J.C., Suaudeau C., Chapouthier G., Costentin J. Mouse lines differing in sensitivity to beta-CCM differ in tasks used for testing antidepressants. Pharmacol Biochem Behav. 72:2002;411-416.
28. Duman R.S. Novel therapeutic approaches beyond the serotonin receptor. Biol Psychiat. 44:1998;324-335.
29. Eckeli A.L., Dach F., Rodrigues A.L. Acute treatments with GMP produce antidepressant-like effects in mice. Neuroreport. 11:2000;1839-1843.
30. Feighner J.P., Boyer W.F. Selective serotonin re-uptake inhibitors. advances in basic research and clinical practice 2nd ed:1996;Wiley & Sons, New York.
31. Frazer A. Antidepressants. J Clin Psychiat. 58:1997;9-25.
32. Furlong R.A., Ho L., Walsh C., Rubinsztein J.S., Jain S., Paykel E.S., Easton D.F., Rubinsztein D.C. Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders. Am J Med Genet. 81:1998;58-63.
33. Gerlai R., Thibodeaux H., Palmer J.T., van Lookeren Campagne M., Van Bruggen N. Transient focal cerebral ischemia induces sensorimotor deficits in mice. Behav Brain Res. 108:2000;63-71.
34. Gobbi G., Murphy D.L., Lesch K., Blier P. Modifications of the serotonergic system in mice lacking serotonin transporters. an in vivo electrophysiological study J Pharmacol Exp Ther. 296:2001;987-995.
35. Heninger G.R., Delgado P.L., Charney D.S. The revised monoamine theory of depression. a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans Pharmacopsychiatry. 29:1996;2-11.
36. Holmes A., Hollon T.R., Liu Z., Sibley D.R., Dreiling J., Gleason T.C., Crawley J.N. Dopamine D5 receptor null mutant mice show attenuated behavioral responses to a dopamine agonist. Behav Neurosci. 115:2001;1129-1144.
37. Holmes A., Yang R.J., Crawley J.N. Evaluation of an anxiety-related phenotype in galanin overexpressing transgenic mice. J Mol Neurosci. 18:2002;151-165.
38. Jenck F., Moreau J.L., Mutel V., Martin J.R., Haefely W.E. Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol. 231:1993;223-229.
39. Liu X., Gershenfeld H.K. Genetic differences in the tail-suspension test and its relationship to imipramine response among 11 inbred strains of mice. Biol Psychiat. 49:2001;575-581.
40. Lucki I., Dalvi A., Mayorga A.J. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berl). 155:2001;315-322.
41. Maes M., Meltzer H.Y. The serotonin hypothesis of depression. Bloom F.E., Kupfer D.J. Psychopharmacology. The Fourth Generation of Progress:1995;933-944 Raven Press, New York.
42. Malison R.T., Price L.H., Berman R., van Dyck C.H., Pelton G.H., Carpenter L., Sanacora G., Owens M.J., Nemeroff C.B., Rajeevan N., Baldwin R.M., Seibyl J.P., Innis R.B., Charney D.S. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiat. 44:1998;1090-1098.
43. Manji H.K., Drevets W.C., Charney D.S. The cellular neurobiology of depression. Nat Med. 7:2001;541-547.
44. Mann J.J. Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology. 21S:1999;99-105.
45. Mann J.J., Huang Y.Y., Underwood M.D., Kassir S.A., Oppenheim S., Kelly T.M., Dwork A.J., Arango V.A. Serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch Gen Psychiat. 57:2000;729-738.
46. Mathews TA, Fedele DE, Unger EL, Lesch KP, Murphy DL, Andrews AM (2000): Effects of serotonin transporter inactivation on extracellular 5-HT levels, in vivo microdialysis recovery and MDMA-induced release of serotonin and dopamine in mouse striatum. Soc Neurosci Abstr 26:624.3.
47. Mayorga A.J., Dalvi A., Page M.E., Zimov-Levinson S., Hen R., Lucki I. Antidepressant-like behavioral effects in 5-hydroxytryptamine(1a) and 5-hydroxytryptamine(1b) receptor mutant mice. J Pharmacol Exp Ther. 298:2001;1101-1107.
48. Mayorga A.J., Lucki I. Limitations on the use of the C57BL/6 mouse in the tail suspension test. Psychopharmacology (Berl). 155:2001;110-112.
49. Menza M.A., Palermo B., DiPaola R., Sage J.I., Ricketts M.H. Depression and anxiety in Parkinson's disease. possible effect of genetic variation in the serotonin transporter J Geriatr Psych Neur. 12:1999;49-52.
50. Montkowski A., Poettig M., Mederer A., Holsboer F. Behavioural performance in three substrains of mouse strain 129. Brain Res. 762:1997;12-18.
51. Montgomery S.A., den Boer J.A. SSRIs in depression and anxiety. 2001;Wiley, New York.
52. Murphy D.L. Neuropsychiatric disorders and the multiple human brain serotonin receptor subtypes and subsystems. Neuropsychopharmacology. 3:1990;457-471.
53. Murphy D.L., Li Q., Engel S., Wichems C., Andrews A., Lesch K.P., Uhl G. Genetic perspectives on the serotonin transporter. Brain Res Bull. 56:2001;487-494.
54. Murphy D.L., Wichems C., Li Q., Heils A. Molecular manipulations as tools for enhancing our understanding of 5-HT neurotransmission. Trends Pharmacol Sci. 20:1999;246-252.
55. Nemeroff C.B., Knight D.L., Franks J., Craighead W.E., Krishnan K.R. Further studies on platelet serotonin transporter binding in depression. Am J Psychiat. 151:1994;1623-1625.
56. O'Neill M.F., Conway M.W. Role of 5-HT(1A) and 5-HT(1B) receptors in the mediation of behavior in the forced swim test in mice. Neuropsychopharmacology. 24:2001;391-398.
57. Owens M.J., Nemeroff C.B. The serotonin transporter and depression. Depress Anxiety. 8S:1998;5-12.
58. Page M.E., Detke M.J., Dalvi A., Kirby L.G., Lucki I. Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology (Berl). 147:1999;162-167.
59. Pälvimäki E.P., Roth B.L., Majasuo H., Laakso A., Kuoppamaki M., Syvalahti E., Hietala J. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl). 126:1996;234-240.
60. Perrault G., Morel E., Zivkovic B., Sanger D.J. Activity of litoxetine and other serotonin uptake inhibitors in the tail suspension test in mice. Pharmacol Biochem Behav. 42:1992;45-47.
61. Pinder R.M., Wieringa J.H. Third-generation antidepressants. Med Res Rev. 13:1993;259-325.
62. Porsolt R.D., Le Pichon M., Jalfre M. Depression. a new animal model sensitive to antidepressant treatments Nature. 266:1977;730-732.
63. Porsolt R.D. Animal models of depression. utility for transgenic research Rev Neurosci. 11:2000;53-58.
64. Ranganathan R., Sawin E.R., Trent C., Horvitz H.R. Mutations in the Caenorhabditis elegans serotonin reuptake transporter MOD-5 reveal serotonin-dependent and -independent activities of fluoxetine. J Neurosci. 21:2001;5871-5884.
65. Ramamoorthy S., Bauman A.L., Moore K.R., Han H., Yang-Feng T., Chang A.S., Ganapathy V., Blakely R.D. Antidepressant- and cocaine-sensitive human serotonin transporter. molecular cloning, expression, and chromosomal localization Proc Natl Acad Sci USA. 90:1993;2542-2546.
66. Redrobe J.P., Bourin M. Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test. Eur J Pharmacol. 325:1997;129-135.
67. Redrobe J.P., MacSweeney C.P., Bourin M. The role of 5-HT1A and 5-HT1B receptors in antidepressant drug actions in the mouse forced swimming test. Eur J Pharmacol. 318:1996;213-220.
68. Rees M., Norton N., Jones I., McCandless F., Scourfield J., Holmans P., Moorhead S., Feldman E., Sadler S., Cole T., Redman K., Farmer A., McGuffin P., Owen M.J., Craddock N. Association studies of bipolar disorder at the human serotonin transporter gene (hSERT; 5HTT). Mol Psychiatr. 2:1997;398-402.
69. Tatsumi M., Groshan K., Blakely R.D., Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 340:1997;249-258.
70. Seretti A., Cusin C., Lattuada E., Di Bella D., Catalano M., Smeraldi E. Serotonin transporter gene (5-HTTLPR) is not associated with depressive symptomatology in mood disorders. Mol Psychiatr. 4:1999;280-283.
71. Smeraldi E., Zanardi R., Benedetti F., Di Bella D., Perez J., Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatr. 3:1998;508-511.
72. Srivastava S.K., Nath C. The differential effects of calcium channel blockers in the behavioural despair test in mice. Pharmacol Res. 42:2000;293-297.
73. Stahl S.M. Not so selective serotonin reuptake inhibitors. J Clin Psychiat. 59:1998;343-344.
74. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test. a new method for screening antidepressants in mice Psychopharmacology (Berl). 85:1985;367-370.
75. Trullas R., Jackson B., Skolnick P. Genetic differences in a tail suspension test for evaluating antidepressant activity. Psychopharmacology (Berl). 99:1989;287-288.
76. van der Heyden J.A., Molewijk E., Olivier B. Strain differences in response to drugs in the tail suspension test for antidepressant activity. Psychopharmacology (Berl). 92:1987;127-130.
77. Vaugeois J.M., Passera G., Zuccaro F., Costentin J. Individual differences in response to imipramine in the mouse tail suspension test. Psychopharmacology (Berl). 134:1997;387-391.
78. Willner P. Antidepressants and serotonergic neurotransmission. an integrative review Psychopharmacology (Berl). 85:1985;387-404.
79. Wong E.H., Sonders M.S., Amara S.G., Tinholt P.M., Piercey M.F., Hoffmann W.P., Hyslop D.K., Franklin S., Porsolt R.D., Bonsignori A., Carfagna N., McArthur R.A. Reboxetine. a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor Biol Psychiat. 47:2000;818-829.
80. Zanardi R., Benedetti F., Di Bella D., Catalano M., Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharm. 201:2000;105-107.
81. Zanardi R., Serretti A., Rossini D., Franchini L., Cusin C., Lattuada E., Dotoli D., Smeraldi E. Factors affecting fluvoxamine antidepressant activity. influence of pindolol and 5-httlpr in delusional and nondelusional depression Biol Psychiat. 50:2001;323-330.